Myla LaiGoldman - West Pharmaceutical Independent Director
| WST Stock | USD 323.32 3.97 1.24% |
Director
Dr. Myla P. LaiGoldman, M.D., is an Independent Director of West Pharmaceutical Services, Inc. Dr. LaiGoldman is the Executive Chair of GeneCentric Therapeutics, Inc.a precision medicine companywhere she previously served as Chief Executive Officer and President since June 2011. She is also managing partner of Personalized Science, LLC, a clinical diagnostics consulting company that she founded in 2008. Previously, Dr. LaiGoldman was Chief Executive Officer and Chief Scientific Officer of CancerGuide Diagnostics, Inc. Before joining CancerGuide Diagnostics, she held various roles including Executive Vice President, Chief Medical Officer and Chief Scientific Officerat Laboratory Corporation of America Holdings LabCorporation and its predecessor company, Roche Biomedical Laboratories, Inc. Additionally, Dr. LaiGoldman was a venture partner at Hatteras Venture Partners since August 2011. Dr. LaiGoldman is Boardcertified in anatomic and clinical pathology. since 2014.
| Age | 62 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 530 Herman O. West Drive, Exton, PA, United States, 19341-1147 |
| Phone | 610 594 2900 |
| Web | https://www.westpharma.com |
West Pharmaceutical Management Efficiency
The company has Return on Asset of 0.1 % which means that on every $100 spent on assets, it made $0.1 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1778 %, implying that it generated $0.1778 on every 100 dollars invested. West Pharmaceutical's management efficiency ratios could be used to measure how well West Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.17 in 2024. Return On Capital Employed is likely to gain to 0.22 in 2024. At this time, West Pharmaceutical's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4 B in 2024, despite the fact that Change To Liabilities is likely to grow to (3.1 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mark Kroll | Haemonetics | 67 | |
| John Forsyth | Baxter International | 73 | |
| Jody Lindell | The Cooper Companies, | 69 | |
| Maria Rivas | The Cooper Companies, | 57 | |
| Kim Duncan | The Cooper Companies, | N/A | |
| Colleen Jay | The Cooper Companies, | 58 | |
| Catherine Burzik | Haemonetics | 70 | |
| Amy Wendell | Baxter International | 60 | |
| Michael Mahoney | Baxter International | 56 | |
| Jeffrey Henderson | Becton Dickinson and | 56 | |
| Marshall Larsen | Becton Dickinson and | 72 | |
| George Babich | Teleflex Incorporated | 69 | |
| Nancy Schlichting | Baxter International | 66 | |
| Christopher Jones | Becton Dickinson and | 65 | |
| Thomas Chen | Baxter International | 71 | |
| Albert Stroucken | Baxter International | 73 | |
| Stephen Klasko | Teleflex Incorporated | 67 | |
| Gary Petersmeyer | The Cooper Companies, | 73 | |
| James Gavin | Baxter International | 73 | |
| Claire Pomeroy | Haemonetics | 65 | |
| Michael Coyle | Haemonetics | 58 | |
Management Performance
West Pharmaceutical Leadership Team
Elected by the shareholders, the West Pharmaceutical's board of directors comprises two types of representatives: West Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of West. The board's role is to monitor West Pharmaceutical's management team and ensure that shareholders' interests are well served. West Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, West Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Buthman, Independent Director | ||
| Deborah Tanner, Independent Director | ||
| Bernard Birkett, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | ||
| Eric Green, President, Chief Executive Officer, Director | ||
| John CFA, Head Relations | ||
| Rudy Poussot, Senior Development | ||
| Kathy DePadua, Senior Officer | ||
| Dr CFA, Vice Relations | ||
| William Feehery, Independent Director | ||
| Aileen RuffPatry, President Manufacturing | ||
| Robert Friel, Independent Director | ||
| Richard Luzzi, VP HR | ||
| Myla LaiGoldman, Independent Director | ||
| Paula Johnson, Independent Director | ||
| Douglas Michels, Independent Director | ||
| Michele Polinsky, Vice Communications | ||
| Kimberly MacKay, Senior Vice President General Counsel, Corporate Secretary | ||
| Don OCallaghan, President Devices | ||
| Paolo Pucci, Independent Director | ||
| Annette Favorite, Chief Human Resource Officer, Senior Vice President | ||
| Patrick Zenner, Independent Chairman of the Board | ||
| Thomas Hofmann, Independent Director | ||
| Silji Abraham, Senior Vice President and Chief Digital and Transformation Officer | ||
| David Montecalvo, Senior Vice President, Chief Operating and Supply Chain Officer | ||
| Christopher Ryan, Senior Vice President of Commercial Products and Emerging Markets | ||
| Quintin Lai, Vice President - Corporate Development, Strategy and Investor Relations | ||
| Molly Joseph, Director | ||
| Andy Polywacz, President Systems | ||
| George Miller, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles CPA, VP Treasurer | ||
| Cindy ReissClark, Senior Vice President of Global Market Units and Commercial Solutions | ||
| Chad Winters, Chief Accounting Officer, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Robert Segura, VP Devel | ||
| Eric Resnick, Chief Technology Officer, Vice President |
West Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is West Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 23.23 B | ||||
| Shares Outstanding | 72.42 M | ||||
| Shares Owned By Insiders | 0.58 % | ||||
| Shares Owned By Institutions | 96.69 % | ||||
| Number Of Shares Shorted | 1.3 M | ||||
| Price To Earning | 40.71 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.